WO1998007426A1 - Methodes de diagnostic de la migraine accompagnee d'aura, de depression et d'angoisse, a partir de variations alleliques de genes dopaminergiques - Google Patents
Methodes de diagnostic de la migraine accompagnee d'aura, de depression et d'angoisse, a partir de variations alleliques de genes dopaminergiques Download PDFInfo
- Publication number
- WO1998007426A1 WO1998007426A1 PCT/US1997/014830 US9714830W WO9807426A1 WO 1998007426 A1 WO1998007426 A1 WO 1998007426A1 US 9714830 W US9714830 W US 9714830W WO 9807426 A1 WO9807426 A1 WO 9807426A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drd2
- alleles
- migraine
- syndrome
- aura
- Prior art date
Links
- 208000000060 Migraine with aura Diseases 0.000 title claims abstract description 62
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 61
- 230000003291 dopaminomimetic effect Effects 0.000 title claims abstract description 56
- 208000019901 Anxiety disease Diseases 0.000 title claims abstract description 54
- 230000036506 anxiety Effects 0.000 title claims abstract description 44
- 238000003745 diagnosis Methods 0.000 title claims abstract description 28
- 102100020756 D(2) dopamine receptor Human genes 0.000 claims abstract description 114
- 101000931901 Homo sapiens D(2) dopamine receptor Proteins 0.000 claims abstract description 113
- 102100029808 D(3) dopamine receptor Human genes 0.000 claims abstract description 64
- 101000865224 Homo sapiens D(3) dopamine receptor Proteins 0.000 claims abstract description 63
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 63
- 238000000034 method Methods 0.000 claims abstract description 49
- 208000024891 symptom Diseases 0.000 claims abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 34
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 238000012216 screening Methods 0.000 claims abstract description 5
- 108700028369 Alleles Proteins 0.000 claims description 171
- 239000003795 chemical substances by application Substances 0.000 claims description 69
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 46
- 229960003638 dopamine Drugs 0.000 claims description 23
- 230000027455 binding Effects 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 19
- 102100029813 D(1B) dopamine receptor Human genes 0.000 claims description 15
- 102100029815 D(4) dopamine receptor Human genes 0.000 claims description 15
- 101000865210 Homo sapiens D(1B) dopamine receptor Proteins 0.000 claims description 15
- 101000865206 Homo sapiens D(4) dopamine receptor Proteins 0.000 claims description 15
- 238000002560 therapeutic procedure Methods 0.000 claims description 15
- 238000011321 prophylaxis Methods 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 230000008499 blood brain barrier function Effects 0.000 claims description 8
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 8
- 230000009870 specific binding Effects 0.000 claims description 7
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 102100020802 D(1A) dopamine receptor Human genes 0.000 abstract 1
- 101000931925 Homo sapiens D(1A) dopamine receptor Proteins 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 42
- 102100033928 Sodium-dependent dopamine transporter Human genes 0.000 description 41
- 208000019695 Migraine disease Diseases 0.000 description 38
- 208000028017 Psychotic disease Diseases 0.000 description 38
- 206010052787 migraine without aura Diseases 0.000 description 34
- 206010027599 migraine Diseases 0.000 description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 102000005962 receptors Human genes 0.000 description 21
- 108020003175 receptors Proteins 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 15
- 239000005557 antagonist Substances 0.000 description 14
- 206010019233 Headaches Diseases 0.000 description 12
- 208000024714 major depressive disease Diseases 0.000 description 11
- 230000003321 amplification Effects 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- 208000019906 panic disease Diseases 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 208000001953 Hypotension Diseases 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000000137 annealing Methods 0.000 description 8
- 230000003474 anti-emetic effect Effects 0.000 description 8
- 239000002111 antiemetic agent Substances 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 230000036543 hypotension Effects 0.000 description 8
- 239000003723 serotonin 1A agonist Substances 0.000 description 8
- 231100000869 headache Toxicity 0.000 description 7
- 101150049660 DRD2 gene Proteins 0.000 description 6
- 208000011688 Generalised anxiety disease Diseases 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 6
- 230000036425 denaturation Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000029364 generalized anxiety disease Diseases 0.000 description 6
- 102000054765 polymorphisms of proteins Human genes 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 5
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 5
- 206010033664 Panic attack Diseases 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 5
- 229960001253 domperidone Drugs 0.000 description 5
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 5
- 208000019899 phobic disease Diseases 0.000 description 5
- 108050004812 Dopamine receptor Proteins 0.000 description 4
- 206010034912 Phobia Diseases 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 4
- 229960001076 chlorpromazine Drugs 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 208000037479 susceptibility to 1 migraine with or without aura Diseases 0.000 description 4
- 108010071131 Autoreceptors Proteins 0.000 description 3
- 102000007527 Autoreceptors Human genes 0.000 description 3
- 102000015554 Dopamine receptor Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 3
- 206010027603 Migraine headaches Diseases 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 101150012893 dat gene Proteins 0.000 description 3
- 238000000556 factor analysis Methods 0.000 description 3
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 3
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 3
- 229960004503 metoclopramide Drugs 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000003518 presynaptic effect Effects 0.000 description 3
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 3
- 229960003111 prochlorperazine Drugs 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 description 2
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 2
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 238000007399 DNA isolation Methods 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 101150097070 Drd3 gene Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229960000276 acetophenazine Drugs 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 229940125683 antiemetic agent Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229960001552 chlorprothixene Drugs 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 229960004170 clozapine Drugs 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- -1 elixirs Substances 0.000 description 2
- 229960000326 flunarizine Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 229960003162 iloperidone Drugs 0.000 description 2
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229950004193 perospirone Drugs 0.000 description 2
- GTAIPSDXDDTGBZ-OYRHEFFESA-N perospirone Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCN3C(=O)[C@@H]4CCCC[C@@H]4C3=O)=NSCC2=C1 GTAIPSDXDDTGBZ-OYRHEFFESA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229960003910 promethazine Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000003523 substantia nigra Anatomy 0.000 description 2
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 2
- MLGCXEBRWGEOQX-UHFFFAOYSA-N tetradifon Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C1=CC(Cl)=C(Cl)C=C1Cl MLGCXEBRWGEOQX-UHFFFAOYSA-N 0.000 description 2
- 229960002784 thioridazine Drugs 0.000 description 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 2
- BXNRTMZZILHVNJ-ZRZAMGCNSA-N (1s,5r)-7-butyl-3-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]-9,9-dimethyl-3,7-diazabicyclo[3.3.1]nonane-2,4,6,8-tetrone Chemical compound O=C([C@@H]1C(=O)N(C([C@H](C2=O)C1(C)C)=O)CCCC)N2CCCCN(CC1)CCN1C1=CC=CC=C1OC BXNRTMZZILHVNJ-ZRZAMGCNSA-N 0.000 description 1
- XUDUTRMKKYUAKI-UHFFFAOYSA-N 3-[1-(1-phenylethyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2C(NC3=CC=CC=C32)=O)CCN1C(C)C1=CC=CC=C1 XUDUTRMKKYUAKI-UHFFFAOYSA-N 0.000 description 1
- GYGUWRJKLIJBQP-UHFFFAOYSA-N 3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl n-(1,3-benzodioxol-5-yl)carbamate;hydrochloride Chemical compound Cl.C1=C2OCOC2=CC(NC(=O)OCCCN2CCC(CC2)C=2C3=CC=C(C=C3ON=2)F)=C1 GYGUWRJKLIJBQP-UHFFFAOYSA-N 0.000 description 1
- GUJRSXAPGDDABA-NSHDSACASA-N 3-bromo-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2,6-dimethoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC GUJRSXAPGDDABA-NSHDSACASA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
- 102100027493 5-hydroxytryptamine receptor 1D Human genes 0.000 description 1
- 101710138068 5-hydroxytryptamine receptor 1D Proteins 0.000 description 1
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 1
- 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 1
- MOFQVDOYTSRLKU-UHFFFAOYSA-N 5-methoxy-3-[4-[4-(4-methoxyphenyl)piperazin-1-yl]butyl]-1h-indole Chemical compound C1=CC(OC)=CC=C1N1CCN(CCCCC=2C3=CC(OC)=CC=C3NC=2)CC1 MOFQVDOYTSRLKU-UHFFFAOYSA-N 0.000 description 1
- PMXOASNGMJAYTN-UHFFFAOYSA-N 8-fluoro-2-(2-pyridin-4-ylethyl)-1,3,4,5-tetrahydropyrido[4,3-b]indole Chemical compound C1C=2C3=CC(F)=CC=C3NC=2CCN1CCC1=CC=NC=C1 PMXOASNGMJAYTN-UHFFFAOYSA-N 0.000 description 1
- NREYMNFZCFNECP-UHFFFAOYSA-N 83507-02-2 Chemical compound C1CN(C)CCC2=CC=CC=C2OC2=CC=CC=C21 NREYMNFZCFNECP-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- TWUJBHBRYYTEDL-UHFFFAOYSA-N Alentemol Chemical compound OC1=CC(CC(N(CCC)CCC)C2)=C3C2=CC=CC3=C1 TWUJBHBRYYTEDL-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000032106 Complicated migraine Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- 102000004073 Dopamine D3 Receptors Human genes 0.000 description 1
- 108090000525 Dopamine D3 Receptors Proteins 0.000 description 1
- 102000003962 Dopamine D4 receptors Human genes 0.000 description 1
- 108090000357 Dopamine D4 receptors Proteins 0.000 description 1
- 102000004084 Dopamine D5 Receptors Human genes 0.000 description 1
- 108090000541 Dopamine D5 Receptors Proteins 0.000 description 1
- 101150043870 Drd4 gene Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000010541 Familial or sporadic hemiplegic migraine Diseases 0.000 description 1
- 101150096839 Fcmr gene Proteins 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019476 Hemiplegic migraine Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 1
- ZZQNEJILGNNOEP-UHFFFAOYSA-N Ocaperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=C(C)N=C4N(C3=O)C=CC=C4C)=NOC2=C1 ZZQNEJILGNNOEP-UHFFFAOYSA-N 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 241001282135 Poromitra oscitans Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 1
- 241000287433 Turdus Species 0.000 description 1
- 208000001407 Vascular Headaches Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 206010048232 Yawning Diseases 0.000 description 1
- WNTYBHLDCKXEOT-UHFFFAOYSA-N acetophenazine Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 WNTYBHLDCKXEOT-UHFFFAOYSA-N 0.000 description 1
- NUKVZKPNSKJGBK-SPIKMXEPSA-N acetophenazine dimaleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 NUKVZKPNSKJGBK-SPIKMXEPSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 101150115889 al gene Proteins 0.000 description 1
- 229950007263 alentemol Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940124433 antimigraine drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000009910 autonomic response Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940054066 benzamide antipsychotics Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- FJTKCFSPYUMXJB-UHFFFAOYSA-N bevantolol hydrochloride Chemical compound [Cl-].C1=C(OC)C(OC)=CC=C1CC[NH2+]CC(O)COC1=CC=CC(C)=C1 FJTKCFSPYUMXJB-UHFFFAOYSA-N 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 229950002871 blonanserin Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229950009739 carvotroline Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 229940068796 clozaril Drugs 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940088505 compazine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010067039 familial hemiplegic migraine Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002640 gastrokinetic effect Effects 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940095895 haldol Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000021005 inheritance pattern Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 229960000423 loxapine Drugs 0.000 description 1
- 229940089527 loxitane Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960000300 mesoridazine Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940028394 moban Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960004938 molindone Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000001009 nucleus accumben Anatomy 0.000 description 1
- 229950010634 ocaperidone Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000001010 olfactory tubercle Anatomy 0.000 description 1
- 230000002746 orthostatic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940107333 phenergan Drugs 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
- 229960003634 pimozide Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- DSKIOWHQLUWFLG-SPIKMXEPSA-N prochlorperazine maleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 DSKIOWHQLUWFLG-SPIKMXEPSA-N 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 239000012658 prophylactic medication Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960003448 remoxipride Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- HKFMQJUJWSFOLY-OAQYLSRUSA-N sarizotan Chemical compound C1=CC(F)=CC=C1C1=CN=CC(CNC[C@@H]2OC3=CC=CC=C3CC2)=C1 HKFMQJUJWSFOLY-OAQYLSRUSA-N 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- RBGAHDDQSRBDOG-UHFFFAOYSA-N setoperone Chemical compound CC=1N=C2SCCN2C(=O)C=1CCN(CC1)CCC1C(=O)C1=CC=C(F)C=C1 RBGAHDDQSRBDOG-UHFFFAOYSA-N 0.000 description 1
- 229950009024 setoperone Drugs 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BGRJTUBHPOOWDU-UHFFFAOYSA-N sulpiride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940028300 tigan Drugs 0.000 description 1
- 229960005013 tiotixene Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
- 229960002324 trifluoperazine Drugs 0.000 description 1
- 229950011472 umespirone Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- AERLHOTUXIJQFV-RCPZPFRWSA-N zalospirone Chemical compound O=C([C@@H]1[C@@H]([C@@H]2C=C[C@H]1[C@H]1C=C[C@H]12)C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 AERLHOTUXIJQFV-RCPZPFRWSA-N 0.000 description 1
- 229950005255 zalospirone Drugs 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Definitions
- the present invention relates generally to the diagnosis and treatment of a syndrome characterized by symptoms of migraine with aura, depression and/or anxiety.
- Migraine headaches are a type of vascular headaches. Migraine headaches are characterized in part as recurrent attacks of headaches, with or without associated visual and gastrointestinal disturbances. Symptoms of migraine headaches usually follow a pattern in each patient. Attacks may be daily or only once in several months. Untreated attacks may last for hours or even days. Nausea, vomiting, photophobia and sonophobia are common. The extremities can become cold and cyanosed, and the patient can become irritable and seek seclusion. In the United States alone, approximately 18 million females and 5.7 million males have been estimated to suffer from severe migraine annually. Migraines are believed to be a leading cause of lost time ' from the workplace.
- migraines A classification of migraines based on patient symptoms has been proposed by the Committee on the Classification of Headache of the International Headache Society, Cephalalgia 8:1-96 (1988). The committee proposes that migraines be classified a migraine without aura (formerly known as common migraine) , migraine with aura (formerly known as classic migraine) and hemiplegic migraine (formerly known as complicated migraine) . Migraine with aura and migraine without aura are the two most frequent forms of migraine.
- a locus for familial hemiplegic migraine has been reported to occur on chromosome 19, Joutel et al . , Mature Genetics 5, 40-45 (1993); Joutel et al . , Am. J. Hum . Genet .
- migraine is neither efficiently diagnosed nor managed (Cephalalgia 8, 96 (1988)). Similarities exist between the epidemiological characteristics of migraine, anxiety and depression (Robins et al., Arch. Gen . Psychiatry 41:949-958(1984); Stewart et al., JAMA 267:64-69 (1992); Rasmussen & Eisen, J Clin Psychiatry 55:5-14 (1994); Kessler et al., Arch. Gen .
- the invention is directed to methods of diagnosing a patient for susceptibility to a syndrome characterized by symptoms of migraine with aura, depression and/or anxiety.
- the methods entail detecting a variant allele of one or more dopaminergic genes in the patient.
- Dopaminergic genes correlated with the syndrome include DRDl, DRD2 , DRD3 and DAT.
- the presence of homozygous Al alleles of the DRD2 Ncol Al gene indicates increased susceptibility to the syndrome relative to the presence of heterozygous A1/A2 alleles
- the presence of heterozygous A1/A2 alleles indicates increased susceptibility relative to the presence of ho ozygous A2/A2 alleles.
- variant alleles are detected in two or more of the DRDl, DRD2 , DRD3 and DAT, and risk factors associated with the presence of each variant allele detected are combined to indicate susceptibility to the syndrome.
- the invention further provides methods of treating a patient suffering from the syndrome described above.
- the patient is administered a therapeutically effective amount of an agent that antagonizes binding of dopamine to DRDl, DRD2 , DRD3 and/or DAT.
- Some such agents lack specific binding to DRD4 and/or DRD5.
- Exemplary agents are shown in Table 1. Some agents are incapable of permeating the blood-brain barrier.
- Agents can be administered intravenously, orally or intramuscularly.
- Agents can be administered therapeutically or prophylactically. Patients amenable to treatment with such methods include those suffering from migraine with aura and having homozygous DRD2 Ncol Al alleles.
- the invention provides methods of screening for a drug effective to treat the syndrome described above.
- drugs are screened by determining their capacity to antagonize binding of dopamine to a dopaminergic receptor or DAT.
- such drugs can be screened for lack of specific binding to DRD4 and/or DRD5.
- the invention provides for the use of an agent that antagonizes binding of dopamine to DRDl, DRD2, DRD3 and/or DAT for the manufacture of a medicament for use in the treatment of a syndrome characterized by symptoms of migraine with aura, depression and/or anxiety in patients having a variant allele of one or more dopaminergic genes.
- dopaminergic genes include DRDl, DRD2 , DRD3 and DAT.
- suitable agents are listed in Table 1.
- the blood-brain barrier is impermeable to passage of the agent.
- Some agents antagonize DRDl, DRD2 , DRD3 and/or DAT without binding to DRD4 or DRD5.
- the variant allele is DRD2 Ncol Al.
- the presence of homozygous Al alleles indicates increased susceptibility to the syndrome relative to the presence of heterozygous A1/A2 alleles, and the presence of heterozygous A1/A2 alleles indicates increased susceptibility relative to the presence of homozygous A2/A2 alleles.
- a patient having homozygous DRD2 Ncol Al alleles has a relatively high susceptibility to the syndrome.
- the syndrome is manifested by symptoms of migraine with aura.
- the medicament is administered intravenously, orally or intramuscularly. In some uses noted above, the medicament is administered prophylactically .
- the invention provides methods for determining the suitability of a patient suffering from a syndrome characterized by symptoms of migraine with aura, depression and/or anxiety for treatment with an agent that antagonizes binding of dopamine to DRDl, DRD2, DRD3 and/or DAT.
- the methods entail detecting a variant allele of one or more dopaminergic genes in the patient.
- Some exemplary agents are listed in Table 1.
- the blood-brain barrier is impermeable to passage of the agent.
- Some agents antagonize DRDl, DRD2, DRD3 and/or DAT without binding to DRD4 or DRD5.
- Such dopaminergic genes include DRDl, DRD2, DRD3 and DAT.
- the variant allele is DRD2 Ncol Al and the presence of homozygous Al alleles indicates increased suitability relative to the presence of heterozygous A1/A2 alleles, and the presence of heterozygous A1/A2 alleles indicates increased susceptibility relative to the presence of homozygous A1/A2 alleles.
- a patient having homozygous DRD2 Ncol Al alleles has a relatively high susceptibility to the syndrome.
- the syndrome is manifested by symptoms of migraine with aura.
- the agent is administered intravenously, orally or intramuscularly.
- the invention further provides for use of an agent that antagonizes binding of dopamine to DRDl, DRD2 , DRD3 and/or DAT for the manufacture of a medicament for therapy.
- a patient is diagnosed for susceptibility to a syndrome characterized by symptoms of migraine with aura, depression and/or anxiety by a method comprising the step of detecting a variant allele of one or more dopaminergic genes in the patient.
- the one or more dopaminergic genes for which a variant allele is detected are selected from DRDl, DRD2 , DRD3 and/or DAT.
- the variant allele is DRD2 Ncol Al and the presence of homozygous Al alleles indicates increased susceptibility to the syndrome relative to the presence of heterozygous A1/A2 alleles, and the presence of heterozygous A1/A2 alleles indicates increased susceptibility relative to the presence of homozygous A2/A2 alleles.
- a patient having homozygous DRD2 Ncol Al alleles has a relatively high susceptibility to the syndrome.
- the syndrome is manifested by symptoms of migraine with aura.
- a therapeutically effective amount of an agent that antagonizes binding of dopamine to DRDl, DRD2 , DRD3 and/or DAT is then administered to the patient.
- Some exemplary agents are listed in Table 1.
- the blood-brain barrier is impermeable to passage of the agent.
- Some agents antagonize DRDl, DRD2 , DRD3 and/or DAT without binding to DRD4 or DRD5
- the agent is administered intravenously, orally or intramuscularly. In some uses, the agent is administered prophylactically.
- the invention further provides diagnostic agents (e.g. , allele-specific probes and primers) , for detecting a variant allele of one or more dopaminergic genes for use in therapy, prophylaxis or diagnosis.
- diagnostic agents e.g. , allele-specific probes and primers
- dopaminergic genes can be selected from DRDl, DRD2 , DRD3 and DAT.
- some diagnostic reagents are used to detect the Ncol Al allele of DRD2.
- the invention further provides agents, such as any of those described above, for use in therapy, prophylaxis or diagnosis of a syndrome characterized by symptoms of migraine with aura, depression and/or anxiety.
- the invention further provides for use of such agent in the therapy, prophylaxis or diagnosis of migraine with aura.
- the invention further provides for the use of an agent for detecting a variant allele of one or more dopaminergic genes for the manufacture of a diagnostic for use in therapy, prophylaxis or diagnosis.
- Preferred dopaminergic genes are selected from DRDl, DRD2 , DRD3 and DAT.
- a suitable variant allele is DRD2 Ncol Al.
- the diagnostic is typically used in the therapy, prophylaxis or diagnosis of a syndrome characterized by symptoms of migraine with aura, depression and/or anxiety. Further, the diagnostic can be used in the therapy, prophylaxis or diagnosis of migraine with aura.
- the invention further provides for the use of an agent that antagonizes binding of dopamine to DRDl, DRD2 , DRD3 and/or DAT for the manufacture of a medicament for use in the treatment of a syndrome characterized by symptoms of migraine with aura, depression and/or anxiety associated with the presence of a variant allele of one or more dopaminergic genes.
- a variant allele is present in one or more dopaminergic genes selected from DRDl, DRD2, DRD3 and DAT.
- the variant allele is DRD2 Ncol Al and the presence of homozygous Al alleles indicates increased susceptibility to the syndrome relative to the presence of heterozygous A1/A2 alleles, and the presence of heterozygous A1/A2 alleles indicates increased susceptibility relative to the presence of homozygous A2/A2 alleles.
- a patient having homozygous DRD2 Ncol Al alleles has a relatively high susceptibility to the syndrome.
- the syndrome is manifested by symptoms of migraine with aura.
- Some exemplary agents are listed in Table 1.
- the blood-brain barrier is impermeable to passage of the agent.
- Some agents antagonize DRDl, DRD2, DRD3 and/or DAT without binding to DRD4 or DRD5.
- the agent is administered intravenously, orally or intramuscularly.
- the agent is administered prophylactically.
- BRIEF DESCRIPTION OF THE DRAWINGS Figure 1A-1D show the percentage of individuals having migraine with aura for different DRDl, DRD2, DRD3 and DAT alleles.
- Figure 2 shows a risk factor analysis of migraine with aura.
- the present invention provides methods of diagnosing and treating a syndrome (mada) characterized by symptoms of, or susceptibility to, migraine with aura, depression and/or anxiety, and resulting, at least in part, from variation in one or more dopaminergic genes.
- a syndrome characterized by symptoms of, or susceptibility to, migraine with aura, depression and/or anxiety
- DRDl, DRD2 , DRD3 and DAT are associated with increased susceptibility to migraine with aura, depression and/or anxiety.
- DRDl, DRD2 and DRD3 are three of five G proteincoupled receptors (DRD1-DRD5) for which dopamine appears to be the primary neurotransmitter . O'Dowd et al., "Dopamine Receptors," in Handbook of Receptors and Channels (ed.
- DRDl is encoded by an intronless gene (Dearry et al . , Nature 347:72-76 (1990); Zhou et al . , Nature 347:76-80 (1990); Sunahara et al . , Nature 347:80-83 (1990)) and is expressed most abundantly in the caudate, nucleus accumbens and olfactory tubercle. DRDl receptors are thought to act as pre-synaptic autoreceptors modulating neurotransmitter release.
- the DRD2 gene has a length of about 270 kb, including six introns, the first of which accounts for about 200 kb of the gene.
- DRD2s are localized in numerous anatomical locations that are believed to play a major role in the pathogenesis of migraine. The highest density of DRD2s are in the substantia nigra and basal ganglia. In the substantia nigra, the DRD2s act as presynaptic autoreceptors which modulate dopamine release (Mengod et al . f Neurochem . Int . 20, 33S-43S (1992)).
- dopamine receptors have been located directly in vascular beds (e.g. , on cerebral arteries) that are believed to be critical in the pathogenesis of migraine.
- dopamine receptors have been localized to pial vessels (Oudart et al . , Arch . Int . Pharmacodyn . 252, 196-209 (1981); Edvinsson et al . , Br. J . Pharmac . 85, 403-410 (1985)) the site of neurogenic inflammation that is believed to play a major role in the headache component of migraine (Moskowitz, Trends Pharmacol . Sci . 13, 307-311 (1992)).
- DRD2s are also located in the peripheral and/or central sympathetic nervous system.
- DRD2s are also located on presynaptic noradrenergic sympathetic ganglia, where they act to inhibit the release from the sympathetic nerve terminals (Clark et al . , Acta Endocrine . , Suppl . 216 88, 75-81 (1978); Ziegler et al . , Clin . Pharmacol . Ther . 25, 137-142
- the DRD3 gene has a high degree of sequence identity with the DRD2 gene (O'Dowd et al . , Handbook of Receptors and Channels : G Protein-coupled Receptors (ed Peroutka, S.J.) 95-123 (CRC Press, Boca Raton, 1994); Sokoloff et al . , Nature 347:146-151 (1990)).
- the DRD3 receptor acts as both a postsynaptic receptor and an autoreceptor which inhibits dopamine release (Tang et al . , J . Pharmacol . Exp. Ther . 270:475-476 (1994)).
- DRD3 has been localized to the limbic areas of the brain (Mengod et al . , Neurochem . Int . 20:33S-43S (1992); Sokoloff et al . , Nature 347:146-151 (1990)) suggesting that it may be associated with cognitive, emotional and endocrine functions. Most drugs that interact with DRD2 also interact with similar affinity with DRD3 (Sokoloff et al . , Nature 347:146-151 (1990)). However, the density of expressed DRD3 receptors is low, estimated at about 1% of that of DRD2 (Accili et al . , Proc . Nat . Acad . Sci . 93:1945-1949 (1996)).
- the dopamine transporter (DAT) gene is a key regulatory protein in the dopamine pathway that modulates the amount of dopamine release and re-uptake (Shimada et al . , Science 254:576-577 (1991)).
- Variant alleles of the dopaminergic genes DRDl, DRD2 , DRD3 and DAT probably cause increased susceptibility to migraine with aura, depression and/or anxiety as a result of increased dopaminergic transmission.
- the proposed role of dopaminergic genes in migraine with aura is consistent with several clinical features of the disease. For example, nausea and/or vomiting are common features of migraine in which dopamine stimulation is likely. Gastrokinetic changes, hypotension and other autonomic nervous system changes are additional migraine symptoms that are consistent with disturbances in dopaminergic neurotransmission.
- the proposed mechanism is also consistent with previous reports of exaggerated autonomic responses to dopamine agonists in migraine patients. For example, apo orphine has been reported to induce symptoms of migraine, as well as the associated phenomenon of nausea, vomiting, yawning, hypotension and syncope (DelZompo et al., Headache 35, 222-224 (1995)).
- the methods of diagnosis and treatment described below usually require knowledge of the genotype of an individual with respect to polymorphisms in the genes DRDl, DRD2, DRD3 , and/or DAT.
- Exemplary polymorphisms within each of these genes that correlate with migraine with aura, depression and/or anxiety are described in the Examples, as are methods for their detection.
- these polymorphisms include: an A to G polymorphism in the 5' untranslated region of DRDl having alleles designated Bl and B2 as described by Cichon et al . , Hum . Hoi . Genet .
- DRD2 TaqI Al allele Noble, Science & Hedicine 3, 52-61 (1996)
- DRD2 Ncol Al can be used in diagnostic methods in a similar manner to DRD2 Ncol Al.
- DRDl, DRD2 , DRD3 and DAT genes that correlate with migraine with aura, anxiety and/or depression can be identified as follows.
- the first step is to identify additional polymorphic sites within one of these genes.
- polymorphic sites can be identified either by comparative sequencing of these genes in a population of individuals or from the published literature and databases.
- additional polymorphic sites in the DRD2 gene have been published including TaqlB within intron 2, Fokl B at position 1105, HphI at position 3208, C311S at position 3413, Ncol at position 3420 and TaqlA within the 3' untranslated region.
- a correlation is performed between type of polymorphic form and presence or absence of migraine with aura, depression, and/or anxiety in a population.
- the correlation can be determined with respect to combinations of two or more polymorphisms within the same gene.
- individuals having the Ncol Al allele are subdivided into two classes respectively having Al and A2 alleles of the Fokl polymorphism.
- Variant genes can be detected, for example, by sequencing, allele-specific amplification (Gibbs, Nucleic Acid Res . 17, 12427-12448 (1989)), restriction enzyme analysis, allele-specific probe hybridization assays (Saiki et al., Nature 324, 163-166 (1986)) or singlestranded conformational analysis (Orita et al., Proc. Natl . Acad . Sci . 86, 2766-2770 (1989)).
- the Ncol Al and A2 alleles can be distinguished by Ncol digestion. Only the A2 allele is cut.
- Reagents used for detecting variant alleles, such as allele specific probes and primers can be packaged as diagnostic reagents. The diagnostic reagents can bear labels indicating their suitability for use in diagnosis of the mada syndrome or a symptom thereof.
- DRD2, DRD3 and/or DAT gene in a patient can be used as a measure of susceptibility to migraine with aura, depression and/or anxiety.
- detection of one or both copies of the Ncol Al allele of DRD2 indicates increased susceptibility to migraine with aura, depression and/or anxiety in the patient, and detection of both copies indicates increased susceptibility relative to one copy.
- Detection of one or both copies of DRDl Bl indicates increased risk of migraine with aura relative to homozygous DRDl B2.
- Detection of homozygous DRD3 A2 indicates increased risk of migraine with aura relative to homozygous or heterozygous DRD3 Al.
- Detection of homozygous DAT 10 indicates increased risk of migraine with aura relative to heterozygous DAT 10/9 and probably 9/9 genotype, although the latter occurs with insufficient frequency to have been included in the present analysis.
- each variant allele associated with the mada syndrome can be assigned a risk factor related to the probability, as discussed in the Examples.
- Fig. 2 shows the percentage of individuals having migraine with aura as a function of number of risk factors present. It can be seen that no individuals without any dopaminergic risk factor have symptoms of the mada syndrome and about 75% of individuals with all five dopaminergic risk factors have symptoms of the mada syndrome. Individuals with 1-4 risk factors show intermediate frequencies of symptoms of the mada syndrome in relation to the number of risk factors present.
- There are probably other genes besides the dopaminergic genes described above having variant forms associated with risk of the mada syndrome The existence of variant forms of such genes can be detected and correlated with probabilities of susceptibility to the syndrome in similar fashion to the analysis of dopaminergic genes. Combined statistical analysis of dopaminergic genes with other genes still further increases the predictive value of the diagnosis.
- the analysis is useful in identifying a subset of patients having a common genetic basis giving rise to the mada syndrome. Such patients are amenable to treatment with antagonists of dopaminergic genes as discussed below. Treatment with such antagonists may be ineffective in other patients, who exhibit similar symptoms to patients with the syndrome, but due to a different genetic basis. This analysis is also useful in distinguishing migraine with aura from migraine without aura, and others diseases, such as stroke, which may present with similar symptoms. That is, a patient with a high number of risk factors for the mada syndrome is more at risk for migraine with aura than for migraine without aura or stroke. IV. Methods of Treatment
- the invention further provides methods of treating patients suffering from, or susceptible to, the mada syndrome.
- a patient having or susceptible to symptoms of migraine with aura, depression and or anxiety is treated with a therapeutically effective dose of an antagonist to one or more of the dopaminergic genes DRDl, DRD2 , DRD3 and DAT.
- Such a dose is sufficient to prevent, arrest or detectably relieve symptoms of migraine with aura, depression and/or anxiety.
- the dose can be administered prophylactically or therapeutically.
- the dose can also be administered to pediatric or handicapped patients but who are unable to articulate their symptoms but are known to have variant forms of one or more variant forms of the dopaminergic genes associated with the disease.
- DRD2 antagonists include phenothiazines (chlorpromazine, fluphenazine, prochlorperazine, promethazine, thioridazine and trifluoperazine) , butyrophenomes (droperidol, haloperidol, pimozide, spiperone) , thioxanthines (chlorprothixene, thiothixene) and other drugs, such as clozapine.
- phenothiazines chlorpromazine, fluphenazine, prochlorperazine, promethazine, thioridazine and trifluoperazine
- butyrophenomes droperidol, haloperidol, pimozide, spiperone
- thioxanthines chlorprothixene, thiothixene
- other drugs such as clozapine.
- Some antagonists are capable of crossing the blood-brain barrier and therefore capable of antagonizing both central and peripheral dopaminergic receptors.
- Other antagonists such as domperidone do not cross the blood-brain barrier and therefore antagonize only peripheral receptors.
- Some agents such as domperidone, metoclopramide, chlorpromazine, prochloperazine and flunarazine have previously been reported to have some value in treating some migraine patients. However, the mechanism of action was not known, not was it appreciated that the agents are most appropriate for administration to the subset of migraine patients having migraine with aura and variant forms of one or more of the dopaminergic genes DRDl, DRD2 , DRD3 , DRD4 and DAT.
- Antagonists can be used to manufacture medicaments for use in treatment of the syndrome.
- Antagonists can be mixed with a pharmaceutical carrier, which can be any compatible, non-toxic substance suitable to deliver the antagonist to the patient.
- a pharmaceutical carrier can be any compatible, non-toxic substance suitable to deliver the antagonist to the patient.
- Sterile water, alcohol, fats, waxes, and inert solids can be used as the carrier.
- Pharmaceutically-acceptable adjuvants, buffering agents, dispersing agents, and the like can also be incorporated into the pharmaceutical compositions.
- concentration of the active agent in the pharmaceutical composition can vary widely, i.e., from less than about 0.1% by weight, usually being at least about 1% by weight to as much as 20% by weight or more.
- Medicaments can be administered intravenously, intramuscularly, subcutaneously, intranasally, cutaneously, via suppository, by inhalation or orally.
- Methods for preparing parenterally administrable compositions are described in more detail in, for example, Remington ' s Pharmaceutical Science (15th ed. , Mack Publishing Company, Easton, Pennsylvania, 1980) (incorporated by reference in its entirety for all purposes) .
- the active ingredient can be administered in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions.
- Active component (s) can be encapsulated in gelatin capsules together with inactive ingredients and powdered carriers, such as glucose, lactose, sucrose, mannitol, starch, cellulose or cellulose derivatives, magnesium stearate, stearic acid, sodium saccharin, talcum, magnesium carbonate and the like.
- inactive ingredients examples include red iron oxide, silica gel, sodium lauryl sulfate, titanium dioxide, edible white ink and the like.
- Similar diluents can be used to make compressed tablets . Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric-coated for selective disintegration in the gastrointestinal tract.
- Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
- the invention further provides methods of screening for novel antagonists of DRDl, DRD2 , DRD3 and/or DAT for treatment of the syndrome.
- Potential agents are screened for specific binding (Kd ⁇ ⁇ M) to human DRDl, DRD2 , DRD3 or DAT, optionally in competition with dopamine.
- Preferred agents bind with a Kd less than 10 nM and can therefore usually be used at a dose of about 10 mg/patient.
- Receptor binding assays can be performed as described by Ison & Peroutka, Cancer Treatment Reports 70, 637 (1986); Peroutka & Snyder, Am . J .
- Some agents are screened for lack of specific binding to at least one of dopaminergic receptors DRD4 or DRD5.
- the agents can also be screened for lack of specific binding to other receptors to minimize side effects. For example, lack of binding to the -adrenergic receptor minimizes orthostatic hypotensive side-effects.
- Preferred agents have a serum half-life of about 24 hr and can reach peak plasma levels within about 15-60 min of administration.
- This example describes analysis of allelic variants within all five dopamine receptor genes (DRDl, DRD2, DRD3, DRD4 and DRD5) and the DAT gene in control, migraine without aura (MO) and MWA individuals.
- Subjects were identified for this study by physician referral. Individuals were evaluated using the diagnostic criteria for MO and MWA established by the International Headache Society (Cephalalgia 8, 1-96 (1988)). The lifetime presence or absence was determined for each of the criteria in the IHS definition of migraine. Interviews were conducted by physicians, nurses and/or trained interviewers. All interviewers were trained by the present inventor in the use of the IHS criteria and all clinical data were reviewed by the same neurologist. Control group individuals did not meet IHS criteria for migraine (based on direct interview) and were predominantly unaffected spouses of the individuals with migraine. Informed consent was obtained and DNA samples collected. All clinical data were obtained independently of the genotypic data. The average age of the study participants is 53 ⁇ 1 years. No variation was observed between the 3 study groups in terms of age, sex or ethnic origin.
- Genotypin A total of 246 DNA samples from unrelated individuals, who were 35 years of age or older, were analyzed (115 control individuals; 77 MO individuals; 54 MWA individuals) . Genomic DNA was isolated using the Puregene DNA isolation kit (Gentra Systems, Research Triangle Park, North Carolina) . Genotypes were scored independently by two individuals blinded to the clinical status. 3. DRDl . DRD2 , DRD3 anc? DRD5 DRDl, DRD2, DRD3 and DRD5 were amplified as follows. Briefly, 40 ng of genomic DNA was amplified in 10 ⁇ L of a solution containing lx Perkin Elmer PCR amplification buffer, 400 ⁇ M each dNTP, 0.5 U TagrGold polymerase
- the enzyme was activated with an initial incubation at 94°C for 10 minutes, followed by 14 cycles of amplification with denaturation at 94°C for 20 seconds, annealing at 63°C for 1 minute, elongation at 72°C for 30 seconds with a decrease of 0.5°C and 3 seconds for each annealing step, and an additional 40 cycles of denaturation at 94°C for 30 seconds, annealing at 56°C for 30 seconds and elongation at 72°C for 1 minute.
- DRD4 genotypes were assessed by amplifying 50 ng of genomic DNA in 10 ⁇ L of lx ThermoPol buffer (New England Biolabs) , 400 uM dNTP, 1 uM of each primer (see Table 2) and 0.2 U Vent (exo " ) Polymerase. Amplification consisted of 35 cycles of denaturation at 98 °C for l minute and annealing/elongation at 70 °C for 5 minutes. Amplification products were analyzed on 1.2% agarose gels.
- DAT DAT genotypes were assessed by amplifying 40 ng of genomic DNA in the presence of 0.5 ⁇ M of fluorescence- labelled dUTP (Applied Biosystems, Foster City, CA) . Reactions progressed through 35 cycles of denaturation at 94 °C for 1 minute and annealing/elongation at 72 °C for 1 minute. Amplified products were analyzed on an ABI 373 sequencer using a 6% polyacrylamide gel. Analysis was performed as described previously (Vandenbergh et al . , Hoi . Brain Res . 15, 161-166 (1992)); Doucette-Stamm et al. Genet . Epidemiol . 12, 303-308 (1995)).
- DRDl 5' UTR B and B2 Allele Frequencies An A to G polymorphism has been described in the 5 ' untranslated region of the DRDl gene (Cichon et al., Hum . Hoi . Genet . 3, 209-209 (1994)).
- n 246 individuals
- the DRDl Bl allele frequency is 0.37
- the B2 allele frequency is 0.63.
- DRD2 iVcoI Al and A2 Allele Frequencies A C to T polymorphism, resulting in a silent mutation at amino acid 313, has been described in the DRD2 gene (Sarkar et al . , Genomics 11, 8-14 (1991).).
- the DRD2 Ncol Al allele frequency is 0.73
- the A2 allele frequency is 0.27.
- the DRD2 Ncol A allele frequencies were also determined in each subgroup of subjects (Table 5) . Similar allele frequencies were observed in both the control group and individuals with MO. By contrast, individuals with migraine with aura had a significantly greater frequency of the DRD2 Al allele (0.83) than either the control group or individuals with migraine without aura.
- a polymorphism resulting in a glycine to serine substitution at position 9 in the ⁇ -terminal part of the DRD3 receptor was analyzed (Lannfelt et al . , Psychiatr. Genet . 2 , 249-256 (1992)).
- the polymorphism consists of a A to G substitution which is 25 bp downstream from the start codon, creating a restriction site for Ball. This polymorphism has been hypothesized to play a role in receptor insertion into the cell membrane (Rietschel et al . , Psychiatr. Res . 46, 253-259 (1993).
- the DRD3 Al allele frequency is 0.62 and the A2 allele frequency is 0.37. These values are similar to the DRD3 allele frequencies reported in previous studies (id.).
- 37% of individuals have the Al/Al genotype, 50% have the A1/A2 genotype and 12% display the A2/A2 genotype.
- A1/A1 (%) A1/ ⁇ 2 (%> A2/A2 (%l Al A2
- D D4 Allele Frequencies The DRD4 gene contains a 48-bp sequence in the third cytoplasmic loop of the receptor that ranges from 2- to 8-fold repeat units (Van Tol et al . , Nature 358, 149-152 (1992) .
- genotypes were obtained on 238 of the 246 individuals.
- 106 individuals 45%
- display the most common genotype i.e., 4/4) whereas 91 individuals (38%) have at least one 7 allele (Table 6).
- the DRD5 Al allele frequency is 0.68 and the A2 allele frequency is 0.32. These values are similar to the DRD5 allele frequencies reported in the North American population (So meret al., Hum . Genet . 92, 633-634 (1993)).
- the overall dataset 47% of individuals have the Al/Al genotype, 43% have the A1/A2 genotype and 10% display the A2/A2 genotype.
- No significant difference was observed in the genotypic distribution between the control group, individuals with MO and individuals with MWA (Table 7) .
- MWA is observed in 22% of the Al/Al individuals, 23% of the A1/A2 individuals and 16% of the A2/A2 individuals. Similar allele frequencies are observed in the control group, individuals with MO and individuals with MWA (Table 7) .
- allelic "risk factors” were identified that were associated independently with an increased susceptibility to MWA compared to alternative genotypes at the same molecular location within the dopaminergic genes: the DRDl Bl/Bl or B1/B2 genotype, the DRD2 Al/Al genotype, the DRD2 A1/A2 genotype, the DRD3 A2/A2 genotype and the DAT 10/10 genotype.
- the strength of the associations varied amongst the different genes, an initial attempt to develop a "risk factor" profile for MWA assigned equal weight to each allelic "risk factor” with a single exception: the DRD2 Al allele.
- Individuals with the DRD2 Al/Al genotype were assigned a risk factor of "2" since the frequency of MWA appeared to be related to the number DRD2 Al alleles present in an individual (Table
- allelic "risk factors” were determined for each individual in the present study (i.e., 0-5 dopaminergic allelic "risk factors” per individual) .
- the frequency of MWA was then determined in each allelic "risk factor” group.
- the data described in this study are derived from a clinical genetic relational database that was developed initially for the genetic analysis of migraine Peroutka & Howell, Towards Higraine 2000 , (Amsterdam, Elsevier Science B.V. , 1996), pp. 35-48. Potential subjects were identified by physician or self-referral. Subjects were evaluated using a semi-structured interview for migraine. Migraine evaluations were conducted by a neurologist and/or trained interviewer. The lifetime presence or absence was determined for each of the criteria in the International Headache Society (IHS) definition of migraine with (MWA) (Cephalalgia 8, 1-96 (1988) .
- IHS International Headache Society
- DSM-III-R Structured Clinical Interview for DSM-III-R
- DSM-IV Diagnostic and Statistical Manual of Mental Disorders-IV
- DSM-IV Diagnostic and Statistical Hanual of Hental Disorders . Vol. 4. (Washington, DC, American Psychiatric Association, 1994) , pp. pp. 317-391 and 393-444) was used to evaluate anxiety and depressive disorders in the same individuals interviewed for migraine.
- the interview included questions that were appropriate to establish a DSM-IV-based diagnosis of generalized anxiety disorder (GAD) , phobias, panic attacks, panic disorder, obsessive-compulsive disorder (OCD) and major depression.
- GAD generalized anxiety disorder
- OCD obsessive-compulsive disorder
- Interviews were performed by physicians or trained psychiatric nurses. Diagnoses required the concurrence of at least 3 physicians.
- Genomic DNA was isolated using the Puregene DNA isolation kit (Gentra Systems, Research Triangle Park, North Carolina) . Genotyping of the DRD2 Ncol polymorphism was performed using previously described primers (Sarkar et al., Genomics 11,8-14 (1991). Briefly, 40 ng of genomic DNA was amplified in 10 uL of a solution containing lx Perkin Elmer PCR amplification buffer, 400 uM each dNTP, 0.5 U TagGold polymerase
- the clinical diagnoses were based on DSM criteria for the anxiety disorders and major depression and on IHS criteria for MWA. If a clear diagnosis could not be made, the individual was "not diagnosed” and was not included in further statistical analyses for the disorder.
- the incidences of the various clinical diagnoses based on DRD2 Ncol genotypes is provided in Table 10.
- a present or past history of MWA, anxiety disorders or major depression is present in 69% of the Al/Al individuals, 53% of the A1/A2 individuals and 22% of the A2/A2 individuals.
- Obsessive ComDulslv ⁇ Disorder 14% 16% 0% 0.01 n.s.
- Major depression, panic attacks, MWA and phobia are also all increased significantly in the Al/Al vs. A2/any individuals (Table 10) .
- both panic disorder and OCD are more frequent in the Al/Al vs. A2/any individuals, the difference does nor reach statistical significance.
- the present data indicate that MWA, anxiety disorders and major depression are comorbidly associated with allelic variations in the DRD2 gene. As a result, some manifestations of these diseases may constitute a distinct clinical syndrome resulting from a single underlying genetic variation. The clinical recognition that all three disorders are associated with the same genetic variant has significant diagnostic and therapeutic implications.
- NNC-22-0031 preclinical psychosis 5-HT3 ant Novo Nordisk A S alpha 1 ant
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP51101298A JP2001527520A (ja) | 1996-08-22 | 1997-08-21 | ドーパミン作動性遺伝子の対立遺伝子変異に由来する、前兆を伴う片頭痛、抑鬱、および不安の診断 |
EP97938536A EP1014977A1 (fr) | 1996-08-22 | 1997-08-21 | Methodes de diagnostic de la migraine accompagnee d'aura, de depression et d'angoisse, a partir de variations alleliques de genes dopaminergiques |
AU40837/97A AU737893B2 (en) | 1996-08-22 | 1997-08-21 | Diagnosis of migraine with aura, depression and anxiety from allelic variations in dopaminergic genes |
CA002263149A CA2263149A1 (fr) | 1996-08-22 | 1997-08-21 | Methodes de diagnostic de la migraine accompagnee d'aura, de depression et d'angoisse, a partir de variations alleliques de genes dopaminergiques |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2439996P | 1996-08-22 | 1996-08-22 | |
US60/024,399 | 1996-08-22 | ||
US3609197P | 1997-01-17 | 1997-01-17 | |
US60/036,091 | 1997-01-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998007426A1 true WO1998007426A1 (fr) | 1998-02-26 |
Family
ID=26698401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/014830 WO1998007426A1 (fr) | 1996-08-22 | 1997-08-21 | Methodes de diagnostic de la migraine accompagnee d'aura, de depression et d'angoisse, a partir de variations alleliques de genes dopaminergiques |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1014977A1 (fr) |
JP (1) | JP2001527520A (fr) |
AU (1) | AU737893B2 (fr) |
CA (1) | CA2263149A1 (fr) |
WO (1) | WO1998007426A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000077261A1 (fr) * | 1999-06-16 | 2000-12-21 | The Rockefeller University | Sensibilite aux dysfonctionnements des neurotransmetteurs detectes au moyen plusieurs reseaux d'echantillons biologiques |
AU761684B2 (en) * | 1999-02-22 | 2003-06-05 | University Of Miami | Minicapsulorhexis valve |
US7910589B2 (en) | 2001-09-25 | 2011-03-22 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
US8030312B2 (en) | 2001-01-29 | 2011-10-04 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1A receptor subtype agonist |
US8703772B2 (en) | 2001-09-25 | 2014-04-22 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5550021A (en) * | 1990-02-07 | 1996-08-27 | Board Of Regents, The University Of Texas System | Allelic diagnosis of susceptibility to compulsive disorder |
-
1997
- 1997-08-21 EP EP97938536A patent/EP1014977A1/fr not_active Withdrawn
- 1997-08-21 WO PCT/US1997/014830 patent/WO1998007426A1/fr not_active Application Discontinuation
- 1997-08-21 JP JP51101298A patent/JP2001527520A/ja active Pending
- 1997-08-21 CA CA002263149A patent/CA2263149A1/fr not_active Abandoned
- 1997-08-21 AU AU40837/97A patent/AU737893B2/en not_active Ceased
Non-Patent Citations (5)
Title |
---|
CATALANO M, ET AL.: "DISTRIBUTION OF A NOVEL MUTATION IN THE FIRST EXON OF THE HUMAN DOPAMINE D4 RECEPTOR GENE IN PSYCHOTIC PATIENTS", BIOLOGICAL PSYCHIATRY, ELSEVIER SCIENCE, NEW YORK, NY; US, 1 January 1993 (1993-01-01), NEW YORK, NY; US, pages 459 - 464, XP002913495, ISSN: 0006-3223, DOI: 10.1016/0006-3223(93)90236-7 * |
Chemical Abstracts Service (C A S); 1 January 1900 (1900-01-01), XP002919280, Database accession no. 127-147925 * |
DATABASE DIALOG MEDLINE 1 January 1900 (1900-01-01), JENSEN S, ET AL: "Linkage Analysis of the D1 Dopamine Receptor Gene and Manic Depression in Six Families", XP002913493, Database accession no. 93093607 * |
DATABASE DIALOG MEDLINE 1 January 1900 (1900-01-01), MITCHELL P: "Exclusion of Close Linkage of Bipolar Disorder to Dopamine D1 and D2 Receptor Gene Markers", XP002913494, Database accession no. 92325300 * |
See also references of EP1014977A4 * |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU761684B2 (en) * | 1999-02-22 | 2003-06-05 | University Of Miami | Minicapsulorhexis valve |
WO2000077261A1 (fr) * | 1999-06-16 | 2000-12-21 | The Rockefeller University | Sensibilite aux dysfonctionnements des neurotransmetteurs detectes au moyen plusieurs reseaux d'echantillons biologiques |
US8680105B2 (en) | 2001-01-29 | 2014-03-25 | Otsuka Pharmaceutical Co., Ltd. | Method of treating down's syndrome |
US8722680B2 (en) | 2001-01-29 | 2014-05-13 | Otsuka Pharmaceutical Co., Ltd. | Method of treating neurodegenerative diseases |
US8030312B2 (en) | 2001-01-29 | 2011-10-04 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1A receptor subtype agonist |
US9387207B2 (en) | 2001-01-29 | 2016-07-12 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1A receptor subtype agonist |
US8426423B2 (en) | 2001-01-29 | 2013-04-23 | Otsuka Pharmaceutical Co., Ltd. | Method of treating Attention Deficit Hyper-Activity Disorder |
US9089567B2 (en) | 2001-01-29 | 2015-07-28 | Otsuka Pharmaceutical Co., Ltd. | Method of treating cognitive impairments and schizophrenias |
US8604041B2 (en) | 2001-01-29 | 2013-12-10 | Otsuka Pharmaceutical Co., Ltd. | Method of treating panic disorder |
US8623874B2 (en) | 2001-01-29 | 2014-01-07 | Otsuka Pharmaceutical Co., Ltd. | Method of treating neurodegenerative diseases |
US8642600B2 (en) | 2001-01-29 | 2014-02-04 | Otsuka Pharmaceutical Co., Ltd. | Method of treating autism |
US9006248B2 (en) | 2001-01-29 | 2015-04-14 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1A receptor subtype agonist |
US8703772B2 (en) | 2001-09-25 | 2014-04-22 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
US7910589B2 (en) | 2001-09-25 | 2011-03-22 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
US8642760B2 (en) | 2001-09-25 | 2014-02-04 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
US8017615B2 (en) | 2001-09-25 | 2011-09-13 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
US8901130B2 (en) | 2001-09-25 | 2014-12-02 | Ostuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation |
US8901303B2 (en) | 2001-09-25 | 2014-12-02 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
US8993761B2 (en) | 2001-09-25 | 2015-03-31 | Otsuka Pharamceutical Co. Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
US8703773B2 (en) | 2001-09-25 | 2014-04-22 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
US8580796B2 (en) | 2001-09-25 | 2013-11-12 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
US9359302B2 (en) | 2001-09-25 | 2016-06-07 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
US8399469B2 (en) | 2001-09-25 | 2013-03-19 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
US10150735B2 (en) | 2001-09-25 | 2018-12-11 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2001527520A (ja) | 2001-12-25 |
EP1014977A4 (fr) | 2000-07-05 |
EP1014977A1 (fr) | 2000-07-05 |
AU4083797A (en) | 1998-03-06 |
CA2263149A1 (fr) | 1998-02-26 |
AU737893B2 (en) | 2001-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10228378B2 (en) | Diagnostic and therapeutic methods and products related to anxiety disorders | |
Cusin et al. | Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity | |
Johann et al. | Comorbidity of alcohol dependence with attention‐deficit hyperactivity disorder: Differences in phenotype with increased severity of the substance disorder, but not in genotype (serotonin transporter and 5‐hydroxytryptamine‐2c receptor) | |
Zai et al. | Evidence for the gamma‐amino‐butyric acid type B receptor 1 (GABBR1) gene as a susceptibility factor in obsessive‐compulsive disorder | |
EP3347013B1 (fr) | Activateur du récepteur métabotropique du glutamate non sélectif pour le traitement du trouble déficitaire de l'attention | |
US7695911B2 (en) | Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof | |
US10098893B2 (en) | Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457 | |
US11957664B2 (en) | Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence | |
CA2851510A1 (fr) | Polymorphismes de nucleotide simple utiles pour predire une reponse clinique a l'acetate de glatiramere | |
US20060286594A1 (en) | Detection of antidepressant induced mania | |
Mannelli et al. | Polymorphism in the serotonin transporter gene and response to treatment in African American cocaine and alcohol‐abusing individuals | |
Patkar et al. | Relationship between serotonin transporter gene polymorphisms and platelet serotonin transporter sites among African-American cocaine-dependent individuals and healthy volunteers | |
AU737893B2 (en) | Diagnosis of migraine with aura, depression and anxiety from allelic variations in dopaminergic genes | |
AU773765B2 (en) | Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of variant GPIIIA and/or variant GPIIB allele | |
US7951538B2 (en) | Method to determine the risk for side effects of an SSRI treatment in a person | |
AU2004258147B2 (en) | Genetic marker of response to atypical antipsychotics and antidepressants and methods for use thereof | |
US20140088035A1 (en) | Treating schizophrenia | |
EP2594649A1 (fr) | Procédé et kit pour prédire une réponse à un traitement antidépresseur | |
Eriksson et al. | Further investigation of citalopram on alcohol consumption in heavy drinkers: responsiveness possibly linked to the DRD2 A2/A2 genotype | |
KR100926269B1 (ko) | 노르아드레날린 재흡수 억제제 계열 항우울제의치료성공율의 예측을 위한 노르아드레날린 수송체의유전자다형성 표지자 | |
Class et al. | Patent application title: DETERMINATION OF SINGLE NUCLEOTIDE POLYMORPHISMS USEFUL TO PREDICT RESPONSE FOR GLATIRAMER ACETATE Inventors: Teva Pharmaceutical Industries, Ltd.(Petach-Tikva, IL) Amir Tchelet (Hod-Hasharon, IL) Fabio Macciardi (Irvine, CA, US) Joseph Levy (Kfar-Sava, IL) Assignees: Teva Pharmaceutical Industries Ltd. | |
Masellis et al. | Pharmacogenetics of psychostimulants in ADHD | |
US20140142150A1 (en) | Treating neuropsychiatric disorders | |
Polley | The Genetics of Autism/PDD: An Investigation of Serotonin, Norepinephrine and Dopamine Transporter Genes in the Etiology of Autism and the Related Pervasive Disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2263149 Country of ref document: CA Ref country code: CA Ref document number: 2263149 Kind code of ref document: A Format of ref document f/p: F |
|
WS | Later publication of a supplementary international search report | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 511012 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997938536 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09242647 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997938536 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997938536 Country of ref document: EP |